Thomas Powles, MBBS
The treatment of patients with kidney cancer will differ greatly in the next decade because of changes in the landscape that occurred in 2017, according to Thomas Powles MBBS, MRCP, MD.
, Powles, a clinical professor of genitourinary oncology, Barts Cancer Institute in London, United Kingdom, discussed the findings from the CheckMate-214 trial, as well as continuing studies in immunotherapy and targeted therapy in kidney cancer, and how this new data might affect the treatment of kidney cancer going forward.
OncLive: Please discuss some of the recent advances in the treatment of patients with kidney cancer.
There has been a change in kidney cancer over the last year. It has been an enormous change; in fact, things will never be the same again. The change has been the essential replacement of frontline VEGF-targeted therapy with combination immunotherapy. That change happened because of a trial called CheckMate-214, which combined ipilimumab and nivolumab. It showed that those 2 drugs in patients with intermediate- or poor-risk disease outperformed sunitinib in terms of response rate and, importantly, overall survival [OS].
... to read the full story